|
|
 |
|
Viewing report
|
|
|
|
The Psychiatric Disease Pipeline: A Strategic Review
Decision Resources, Inc., July 2009, Pages: 27
Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications, 28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth in recent years, sustained franchise sales, tolerance for use of multiple drugs within a drug class, and a clinical pipeline of more than 150 agents. Given the heterogeneity of the patient populations in the psychiatric disease sector, unmet need and commercial opportunity are high. We explore ways in which companies are using strategic differentiation and novel targets to overcome challenges and tap sales potential.
Questions Answered in This Report
A database search of agents in development for psychiatric disease yields nearly 300 agents. From this list, we have confirmed that more than 150 of the agents are still in clinical development for psychiatric diseases.
- What are the most common indication and mechanism targets of development?
- How advanced is the pipeline overall?
- What companies are most active in psychiatric drug development?
Unmet needs create opportunities for emerging agents.
- What are the unmet needs specific to psychiatric indications?
- Are there any drugs in the pipeline that promise to address these unmet needs?
Eli Lilly leads the psychiatric sector in terms of sales; GlaxoSmithKline (GSK), another sales leader, stands out with the largest pipeline; and AstraZeneca (AZ) is notable for being a sales leader with just one marketed psychiatric disease agent.
- What accounts for the success of these companies to date?
- How are they defending their leadership positions?
- What other companies are vying for prime positions in this sector?
With many drugs on the market and many of them available generically, competition is intense in this marketplace.
- What strategies have companies used to preserve patient share and market share?
- How are makers of emerging agents likely to position their products?
Scope
2008 market: 2008 sales; leading drug classes; market-leading companies; commercial position of leading agents.
Psychiatric disease pipeline: number of agents in development; disease focus; active companies; profiles of GSK and AZ; mechanisms of action; company type; phase analysis; novel formulations versus reformulations.
Psychiatric diseases focused on in this report: schizophrenia; depression; anxiety; addiction; attention-deficit/hyperactivity disorder (ADHD); cognitive impairment associated with schizophrenia (CIAS).
Opportunities in psychiatric diseases: unmet needs of current treatments; treatment-resistant depression; bipolar depression; CIAS; line extensions.
Challenges in psychiatric diseases: availability of generics; PCP versus specialist prescribing; reimbursement issues. products?
Mentioned in This Report
- Addiction
- Attention-deficit hyperactivity disorder
- Bipolar disorder
- Generalized anxiety disorder
- Major depressive disorder
- Panic disorder
- Schizophrenia
- Social anxiety disorder
Customers who bought this item also bought
Novel therapeutics and future R&D
Special Report: The Autoimmune Biologics Pipeline-A Competitive Review
The Immune/Inflammatory Pipeline: A Strategic Review
Product Profiles: Depression - Next generation vies for second-line patients
Bipolar Disorder: Clinical and Neurobiological Foundations
Emerging Diagnostic Technologies for Use in Psychiatric Indications
Dealmaking and Industry Outlook in Niche Metabolic Diseases
Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012
Inhaled CNS Therapeutics - Markets & Opportunities
Antiageing and Life Enhancement Pharmacotherapeutics: Rejuvenating Drug Markets To 2012 and Beyond
|
|
|
|
